Advertisement

International Urology and Nephrology

, Volume 52, Issue 1, pp 121–128 | Cite as

Adjunctive acetazolamide therapy for the treatment of Bartter syndrome

  • Mojgan Mazaheri
  • Farahnak AssadiEmail author
  • Simin Sadeghi-Bojd
Nephrology - Original Paper
  • 31 Downloads

Abstract

Purpose

Bartter syndrome is a rare hereditary salt-losing tubulopathy caused by mutations of several genes in the thick ascending limb of Henle’s loop, characterized by polyuria, hypokalemic metabolic alkalosis, growth retardation and normal blood pressure. Cyclooxygenase inhibitors, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors are currently used to treat electrolyte derangements, but with poor response. Whether treatment with acetazolamide, a carbonic-anhydrase inhibitor, would result in better clinical outcomes is unknown.

Methods

We randomly assigned children with Bartter syndrome in a 1:1 ratio to either receive indomethacin, enalapril, and spironolactone or indomethacin, enalapril, and spironolactone plus acetazolamide once daily in the morning for 4 weeks. After 2 days of washout, participants crossed over to receive the alternative intervention for 4 weeks. The present study examines the serum bicarbonate lowering effect of acetazolamide as an adjunctive therapy in children with Batter syndrome.

Results

Of the 43 patients screened for eligibility, 22 (51%), between the ages 6 and 42 months, were randomized to intervention. Baseline characteristics were similar between the two groups. Addition of acetazolamide for a period of 4 weeks significantly reduced serum bicarbonate and increased serum potassium levels, parallel with a reduction in serum aldosterone and plasma renin concentration. The 24-h urine volume, sodium, potassium, and chloride decreased significantly.

Conclusion

Our data define a new physiologic and therapeutic role of acetazolamide for the management of children with Bartter syndrome.

Keywords

Acetazolamide Bartter syndrome Children Hypokalemia Metabolic alkalosis 

Notes

Acknowledgements

Authors are grateful to the patients and their families for participating in this study. The authors would also like to thank the nursing staff of the participating medical centers for their contributions and administrative support during this study period.

Authors’ contributions

MM contributed significantly to analysis and interpretation of data, drafting the article. FA contributed to the design and conception of the study, analysis and interpretation of data and providing intellectual content of critical importance to the work submitted. SS contributed to acquisition, analysis, and interpretation of data. All authors read and approved the final version of the work to be published and accept the responsibility of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors.

Compliance with ethical standards

Conflict of interest

Authors acknowledge that the submitted article is original, has not been published previously in whole or part, and is not currently under review elsewhere. Authors further declare that there is no financial support or relationships that may pose conflict of interest regarding the content of this article.

Ethical approval

All procedures performed in this study were in accordance with ethical standards of the appropriate institutional research ethics committee on human experimentation and has been performed in accordance with the ethical standards as laid in the 1964 Declaration of Helsinki and its later amendments as revised in 2013 and followed the CONSORT 2010 checklist guidelines for reporting the randomized clinical trial (Clinical Trial Registration Reference: IR.ZAUMS.REC.1397.492).

Informed consent

Written parental informed consent was obtained for all participants prior to the study.

References

  1. 1.
    Bartter FC, Pronove P, Gill JR, MacCardle RC (1962) Hyperplasia of juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis: a new syndrome. Am J Med 33:811–828CrossRefGoogle Scholar
  2. 2.
    Cunha TDS, Heilberg IP (2018) Bartter syndrome: causes, diagnosis, and treatment. Int J Nephrol Renovasc Dis 11:291–301CrossRefGoogle Scholar
  3. 3.
    Seyberth HW, Weber S, Komhoff M (2017) Bartter’s and Gitelman’s syndrome. Curr Opin Pediatr 29:179–186CrossRefGoogle Scholar
  4. 4.
    Batter FC, Gill JR, Frolich JC, Bowden RE, Taylor AA, Keiser HR et al (1976) Prostaglandins are overproduced by the kidney and mediate hyperreninemia in Bartter’s syndrome. Trans Assoc Am Phys. 89:77–91Google Scholar
  5. 5.
    Boone M, Dean PMT (2008) Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch 456:1005–1024CrossRefGoogle Scholar
  6. 6.
    Ares GR, Gaceres PS, Ortiz PA (2011) Molecular regulation of NKCC2 in the thick ascending limb. Am J Physiol Renal Physiol 301:F1143–F1159CrossRefGoogle Scholar
  7. 7.
    Simon DB, Karet FE, Hamdam JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter’s syndrome, hypokalemic alkalosis with hypercalciuria, is caused by mutations in the Na–K–2Cl cotransporter NKCC2. Nat Genet 13:183–188CrossRefGoogle Scholar
  8. 8.
    Carmosino M, Procino G, Svelto M (2012) Na+ -K+ -2Cl–cotransporter type 2 trafficking and activity: the role of interacting proteins. Bil Cell 104:201–221CrossRefGoogle Scholar
  9. 9.
    Simon DB, Karet EE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H et al (1996) Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nati Genet 14:152–156CrossRefGoogle Scholar
  10. 10.
    Seyes E, Andrini O, Kecj M, Mansour-Hendill L, Courand PY, Simin C et al (2017) Clinical and genetic spectrum of Bartter syndrome type 3. J Am Soc Nephrol 28:2540–2552CrossRefGoogle Scholar
  11. 11.
    Simon DB, Binda RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R et al (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter’s syndrome type 111. Nat Genet 117:171–178CrossRefGoogle Scholar
  12. 12.
    Dane B, Yayla M, Dane C (2007) Prenatal diagnosis of Bartter syndrome with biochemical examination of amniotic fluid: case report Fetal Diag Ther 22:206–208Google Scholar
  13. 13.
    Komhoff M, Laghmani K (2017) Pathophysiology of antenatal Bartter’s syndrome. Curr Opin Nephrol Hypertens 26:419–425CrossRefGoogle Scholar
  14. 14.
    Najafi M, Koerdi-Tamandani DM, Behjati F, Sadeghi-Bojd S, Bakey Z, Karimiani EG et al (2019) Mimicry and well known genetic friends: molecular diagnosis in an Iranian cohort of suspected Batter syndrome and proposition of an algorithm for clinical differential diagnosis. Orphanet J Rare Dis 14:41.  https://doi.org/10.1186/s13023-018-0981-5 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Brikenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I et al (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310–314CrossRefGoogle Scholar
  16. 16.
    Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K et al (2008) Molecular analysis of digenetic inheritance in Bartter syndrome with sensonrineual deafness. J Med Genet 45:182–186CrossRefGoogle Scholar
  17. 17.
    Laghmani K, Beck BB, Yang S-S, Seaayfan E, Wenzel A, Reusch B et al (2016) Polyhydramnios, transient antenatal Bartter’s syndrome, and MAGED2 mutations. N Engl J Med 374:1853–1863CrossRefGoogle Scholar
  18. 18.
    Watanable S, Fukumoto S, Chang H, Takeuch Y, Hasegawa Y, Okazaki R et al (2002) Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. Lancet 360:692–694CrossRefGoogle Scholar
  19. 19.
    Gasongo G, Greebaum LA, Neil O, Kwon T, Macher MA, Maisin A et al (2019) Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome. Pediatr Nephrol 34:679–684CrossRefGoogle Scholar
  20. 20.
    Reinalter SC, Jecj N, Brochhausen C, Watzer B, Nusing RM, Seyberth HW et al (2002) Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 62:253–260CrossRefGoogle Scholar
  21. 21.
    Nascimento CLP, Garcia CL, Schvartsman BGS, Vaisbich MH (2014) Treatment of Bartter syndrome, unsolved issue. J Pediatr 90:512–517CrossRefGoogle Scholar
  22. 22.
    Vaisbich MH, Fujimura MD, Koch VH (2004) Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 19:858-563CrossRefGoogle Scholar
  23. 23.
    White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX et al (2007) Risk of cardiovascular events in patients receiving celecoxib: a metaanalysis of randomized clinical trials. Am J Cardiol 99:91–98CrossRefGoogle Scholar
  24. 24.
    Preisig PA, Toto RD, Alpern RJ (2005) Carbonic anhydrase inhibitors. Renal Physiol 10:136–159Google Scholar
  25. 25.
    Assadi F (2005) Acetazolamide for prevention of contrast-induce nephropathy: a new use for an old drug. Pediat Cardiol 27:238–242CrossRefGoogle Scholar
  26. 26.
    Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–663CrossRefGoogle Scholar
  27. 27.
    Altman DG, Anderson PK (1999) Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 319:1492–1495CrossRefGoogle Scholar
  28. 28.
    Assadi F (2011) A practical approach to metabolic alkalosis. In: Elzouki AY, Harfi HA, Nazer H (eds) Textbook of clinical pediatrics, 2nd edn. Springer, New York, pp 2671–2676Google Scholar
  29. 29.
    Andrews MG, Johnson PN, Lammers EM, Harrison DL, Miller JL (2013) Acetazolamide in critically ill neonates with metabolic alkalosis. Ann Pharmacother 47:1130–1135CrossRefGoogle Scholar
  30. 30.
    Lopez C, Alcaraz AJ, Toledo B, Cortejoso L, Gil-Ruitz MA (2016) Acetazolamide therapy for metabolic alkalosis in pediatric intensive care patients. Pediatri Crit Care Med 17:e551–e555CrossRefGoogle Scholar
  31. 31.
    Peixoto AJ, Alpern RJ (2013) Treatment of severe metabolic alkalosis in a patient with congestive heart failure. Am J Kidney Dis 61:822–827CrossRefGoogle Scholar
  32. 32.
    Bar A, Cies J, Stapleton K, Tauber D, Chopra A, Shore PM (2015) Acetazolamide therapy for metabolic alkalosis in critically ill pediatric patients. Pediatr Crit Care Med 16:3e4-4CrossRefGoogle Scholar
  33. 33.
    Zingerman B, Herman-Edelstein M, Eman A, Bar Sheshet Itach S, Ori Y, Rozen-Zvi B et al (2015) Effect of Acetazolamide on obesity-induced glomerular hyperfiltration: a randomized control trail. Plos One 10(9):e0137163.  https://doi.org/10.1371/journal.pone.0137163 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Yeyati NL, Alternberg GA, Adrogue HJ (1992) Mechanism of acetazolamide-induced rise in renal vascular resistance assessed in the dog whole kidney. Ren Physiol Biochem 15:99–105PubMedGoogle Scholar
  35. 35.
    Skott P, Hommel E, Bruun NE, Arnold-Larsen S, Parving HH (1989) Theacute effect of acetazolamide on glomerular filtration rate and proximal tubular reabsorption of sodium and water in normal man. Scand J Clin Lab Invest 49:583–587CrossRefGoogle Scholar
  36. 36.
    Slomowitz LA, Bergamo R, Hirschberg R, Grosvenor M, Kopple JD (1996) Enalapril attenuated the renal hemodynamic effect of acetazolamide in patients with diabetes mellitus: possible implications for tubuloglomerular feedback. Am J Nephrol 16:315–319CrossRefGoogle Scholar
  37. 37.
    Hannedouche T, Lazzo M, Delgado AG, Boilard C, Lacour B, Grunfeld JP (1991) Feedback mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients. Clin Sci 81:457–464CrossRefGoogle Scholar
  38. 38.
    Galler M, Backenroth R, Folkert VW, Schlondorff D (1982) Effect of converting enzyme inhibitors on prostaglandin synthesis by isolated glomeruli and aortic strips from rats. J Pharmacol Exp Ther 220:23–28PubMedGoogle Scholar
  39. 39.
    Maisey DN, Brown RD (1981) Acetazolamide and symptomatic metabolic acidosis in mild renal failure. Br Med J 283:1527–1529CrossRefGoogle Scholar
  40. 40.
    Dorris R, Olivia JV, Rodman T (1964) Dichlorphenamide, a potent carbonic anhydrase inhibitor: effect on alveolar ventilation, ventilation-perfusion relationships and diffusion in patients with chronic lung disease. Am J Med 36:79–86CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Pediatrics, Section of NephrologySemnan University of Medical ScienceSemnanIran
  2. 2.Department of Pediatrics, Division of NephrologyRush University Medical CenterChicagoUSA
  3. 3.Department of Pediatrics, Division of NephrologyZahedan University of Medical SciencesZahedanIran

Personalised recommendations